Log In
Print this Print this

ARQ 531

  Manage Alerts
Collapse Summary General Information
Company ArQule Inc.
DescriptionReversible inhibitor of the wild type and mutant (C481S) forms of BTK
Molecular Target Bruton's tyrosine kinase (Btk)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat ibrutinib resistant cancers
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today